$ORC
Orchid Island Capital, Inc.

2021 Q3 Form 10-Q Financial Statement

#000151862121000112 Filed on July 30, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $34.17M $29.25M $27.26M
YoY Change 25.52% 7.32% -25.23%
Cost Of Revenue $3.726M $3.348M $5.750M
YoY Change 12.91% -41.77% -75.8%
Gross Profit $27.56M -$14.94M $50.26M
YoY Change -7.13% -129.72% 899.2%
Gross Profit Margin 80.65% -51.06% 184.39%
Selling, General & Admin $3.674M $3.719M $2.756M
YoY Change 28.96% 34.94% -2.3%
% of Gross Profit 13.33% 5.48%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.674M $3.719M $2.756M
YoY Change 28.96% 34.94% -2.3%
Operating Profit $23.88M -$18.66M $47.50M
YoY Change -10.96% -139.27% 2050.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.140M
YoY Change -2.4%
Pretax Income $26.04M -$16.87M $48.77M
YoY Change -7.27% -134.58% 1281.59%
Income Tax
% Of Pretax Income
Net Earnings $26.04M -$16.87M $48.77M
YoY Change -7.26% -134.58% 1280.47%
Net Earnings / Revenue 76.2% -57.65% 178.93%
Basic Earnings Per Share $0.20 -$0.17 $0.74
Diluted Earnings Per Share $0.20 -$169.5K $0.73
COMMON SHARES
Basic Shares Outstanding 123.1M shares 99.49M shares 66.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $424.1M $272.8M $175.3M
YoY Change 112.28% 55.64% 29.28%
Cash & Equivalents $424.1M $272.8M $175.3M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $700.0K
Other Receivables $15.24M $12.55M $10.30M
Total Short-Term Assets $439.4M $285.4M $186.3M
YoY Change 109.03% 53.19% 24.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.639B $4.671B $3.445B
YoY Change 59.27% 35.61% -2.35%
Other Assets $51.11M $106.9M $60.80M
YoY Change 7.6% 75.78% 85.93%
Total Long-Term Assets $5.738B $4.823B $3.514B
YoY Change 59.26% 37.23% -1.77%
TOTAL ASSETS
Total Short-Term Assets $439.4M $285.4M $186.3M
Total Long-Term Assets $5.738B $4.823B $3.514B
Total Assets $6.177B $5.108B $3.700B
YoY Change 62.0% 38.04% -0.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $935.0K $794.0K $600.0K
YoY Change 55.83% 32.33% 0.0%
Accrued Expenses $753.0K $1.042M $700.0K
YoY Change -5.88% 48.86% -93.07%
Deferred Revenue
YoY Change
Short-Term Debt $5.214B $4.515B $3.315B
YoY Change 58.9% 36.21% -0.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.406B $4.524B $3.320B
YoY Change 58.96% 36.29% -0.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $40.35M $29.90M $34.90M
YoY Change 13.97% -14.32% 53.74%
Total Long-Term Liabilities $40.35M $29.90M $34.90M
YoY Change 13.97% -14.32% 53.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.406B $4.524B $3.320B
Total Long-Term Liabilities $40.35M $29.90M $34.90M
Total Liabilities $5.447B $4.554B $3.354B
YoY Change 58.5% 35.76% -0.38%
SHAREHOLDERS EQUITY
Retained Earnings -$38.19M -$62.55M
YoY Change 10.78% 106.73%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $730.6M $553.8M $346.0M
YoY Change
Total Liabilities & Shareholders Equity $6.177B $5.108B $3.700B
YoY Change 62.0% 38.04% -0.71%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $26.04M -$16.87M $48.77M
YoY Change -7.26% -134.58% 1280.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $22.53M $13.89M $19.16M
YoY Change 19.74% -27.52% 11.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$779.1M -$401.6M -$336.4M
YoY Change 562.66% 19.39% -26.51%
Cash From Investing Activities -$779.1M -$401.6M -$336.4M
YoY Change 562.66% 19.39% -26.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 852.1M 438.9M 351.8M
YoY Change 674.13% 24.74% -26.52%
NET CHANGE
Cash From Operating Activities 22.53M 13.89M 19.16M
Cash From Investing Activities -779.1M -401.6M -336.4M
Cash From Financing Activities 852.1M 438.9M 351.8M
Net Change In Cash 95.53M 51.12M 34.58M
YoY Change 743.87% 47.84% -9.38%
FREE CASH FLOW
Cash From Operating Activities $22.53M $13.89M $19.16M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
orc Effect Of Weighting
EffectOfWeighting
-812000 shares
CY2021Q2 orc Effect Of Weighting
EffectOfWeighting
-18011000 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-74822000 USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117500013 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76073317 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001518621
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
13483000 USD
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Shell Company
EntityShellCompany
false
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35236
dei Entity Registrant Name
EntityRegistrantName
Orchid Island Capital, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MD
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3269228
dei Entity Address Address Line1
EntityAddressAddressLine1
3305 Flamingo Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Vero Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32963
dei City Area Code
CityAreaCode
772
dei Local Phone Number
LocalPhoneNumber
231-1400
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
ORC
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123060013 shares
CY2021Q2 us-gaap Financial Instruments Owned And Pledged As Collateral At Fair Value
FinancialInstrumentsOwnedAndPledgedAsCollateralAtFairValue
4665578000 USD
CY2020Q4 us-gaap Financial Instruments Owned And Pledged As Collateral At Fair Value
FinancialInstrumentsOwnedAndPledgedAsCollateralAtFairValue
3719906000 USD
CY2020Q4 us-gaap Financial Instruments Owned And Not Pledged At Fair Value
FinancialInstrumentsOwnedAndNotPledgedAtFairValue
6989000 USD
CY2021Q2 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
4671239000 USD
CY2020Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
3726895000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272842000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
220143000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
106876000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
79363000 USD
CY2021Q2 us-gaap Interest Receivable
InterestReceivable
12547000 USD
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
9721000 USD
CY2021Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
43735000 USD
CY2020Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
20999000 USD
CY2020Q4 us-gaap Other Receivables From Broker Dealers And Clearing Organizations
OtherReceivablesFromBrokerDealersAndClearingOrganizations
414000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
516000 USD
CY2021Q2 us-gaap Assets
Assets
5107927000 USD
CY2021Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
1352000 USD
CY2020Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
3360000 USD
us-gaap Repurchase Agreements Interest Expense Amount
RepurchaseAgreementsInterestExpenseAmount
21002000 USD
CY2021Q2 us-gaap Repurchase Agreements Interest Expense Amount
RepurchaseAgreementsInterestExpenseAmount
1556000 USD
CY2020Q2 us-gaap Repurchase Agreements Interest Expense Amount
RepurchaseAgreementsInterestExpenseAmount
4479000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
52613000 USD
CY2020Q4 us-gaap Assets
Assets
4058051000 USD
CY2021Q2 us-gaap Securities Sold Under Agreements To Repurchase
SecuritiesSoldUnderAgreementsToRepurchase
4514704000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
41927000 USD
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
27698000 USD
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
22779000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-6045000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-25020000 USD
CY2021Q2 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
16769000 USD
CY2020Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
33227000 USD
CY2020Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1157000 USD
CY2021Q2 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
794000 USD
CY2021Q2 us-gaap Other Liabilities
OtherLiabilities
13134000 USD
CY2020Q4 us-gaap Securities Sold Under Agreements To Repurchase
SecuritiesSoldUnderAgreementsToRepurchase
3595586000 USD
CY2021Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
7663000 USD
CY2020Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
4970000 USD
CY2020Q4 us-gaap Other Liabilities
OtherLiabilities
7188000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
4554106000 USD
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
761000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
432524000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17994000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
553821000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5107927000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
56110000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
62929000 USD
CY2021Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
29254000 USD
CY2020Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
27258000 USD
us-gaap Repurchase Agreements Interest Expense Amount
RepurchaseAgreementsInterestExpenseAmount
3497000 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-96147000 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
37272000 USD
us-gaap Management Fee Expense
ManagementFeeExpense
2645000 USD
CY2021Q2 us-gaap Management Fee Expense
ManagementFeeExpense
1792000 USD
CY2020Q2 us-gaap Management Fee Expense
ManagementFeeExpense
1268000 USD
us-gaap Cost Of Goods And Services Sold Overhead
CostOfGoodsAndServicesSoldOverhead
799000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3719000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2756000 USD
us-gaap Profit Loss
ProfitLoss
-42427000 USD
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-7281000 USD
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
34240000 USD
CY2021Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-34915000 USD
CY2020Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-8851000 USD
orc Net Portfolio Income
NetPortfolioIncome
-39022000 USD
orc Net Portfolio Income
NetPortfolioIncome
-37530000 USD
CY2021Q2 orc Net Portfolio Income
NetPortfolioIncome
-13146000 USD
CY2020Q2 orc Net Portfolio Income
NetPortfolioIncome
51528000 USD
us-gaap Management Fee Expense
ManagementFeeExpense
3413000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-16865000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
48772000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
10557000 USD
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-91709000 USD
us-gaap Cost Of Goods And Services Sold Overhead
CostOfGoodsAndServicesSoldOverhead
695000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold Overhead
CostOfGoodsAndServicesSoldOverhead
395000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold Overhead
CostOfGoodsAndServicesSoldOverhead
348000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
625000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
-275000 USD
CY2021Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
261000 USD
CY2020Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
161000 USD
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
595000 USD
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
508000 USD
CY2021Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
323000 USD
CY2020Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
248000 USD
us-gaap Professional Fees
ProfessionalFees
620000 USD
us-gaap Professional Fees
ProfessionalFees
601000 USD
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
302000 USD
CY2020Q2 us-gaap Professional Fees
ProfessionalFees
346000 USD
orc Direct Reit Operating Expenses
DirectReitOperatingExpenses
715000 USD
orc Direct Reit Operating Expenses
DirectReitOperatingExpenses
446000 USD
CY2021Q2 orc Direct Reit Operating Expenses
DirectReitOperatingExpenses
294000 USD
CY2020Q2 orc Direct Reit Operating Expenses
DirectReitOperatingExpenses
240000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
445000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
277000 USD
CY2021Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
352000 USD
CY2020Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
145000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7212000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4897000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92456082 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65408722 shares
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99489065 shares
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66310219 shares
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.390
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.405
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
172000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-115000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
162000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12063000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2986864000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
395507000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-91199000 USD
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63062000 shares
CY2021Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.195
orc Proceeds From Securities Sold Under Agreements To Repurchase
ProceedsFromSecuritiesSoldUnderAgreementsToRepurchase
13582422000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
34927000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
395507000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-91199000 USD
CY2020Q1 us-gaap Dividends
Dividends
15670000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3171000 shares
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19447000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
4000 shares
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
59000 USD
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66237000 shares
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
308144000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
48772000 USD
CY2020Q2 us-gaap Dividends
Dividends
10935000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
55000 USD
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
20000 shares
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-68000 USD
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66221000 shares
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
345968000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
415291000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-29369000 USD
CY2021Q1 us-gaap Dividends
Dividends
17226000 USD
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
18248000 shares
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96908000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
572000 USD
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94411000 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
466176000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-16865000 USD
CY2021Q2 us-gaap Dividends
Dividends
20416000 USD
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
23087000 shares
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
124746000 USD
CY2021Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
2000 shares
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
180000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
553821000 USD
us-gaap Profit Loss
ProfitLoss
-46234000 USD
us-gaap Profit Loss
ProfitLoss
-42427000 USD
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
429000 USD
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
114000 USD
us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
-102192000 USD
us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
12252000 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
2826000 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-2163000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-10395000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1305000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
671000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-53000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
38648000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1985756000 USD
orc Proceeds From Sale Of Mortgage Backed Securities Mbs Categorized As Trading
ProceedsFromSaleOfMortgageBackedSecuritiesMbsCategorizedAsTrading
1680903000 USD
orc Proceeds From Sale Of Mortgage Backed Securities Mbs Categorized As Trading
ProceedsFromSaleOfMortgageBackedSecuritiesMbsCategorizedAsTrading
2023334000 USD
orc Proceeds From Maturities Prepayments And Calls Of Mortgage Backed Securities Categorized As Trading
ProceedsFromMaturitiesPrepaymentsAndCallsOfMortgageBackedSecuritiesCategorizedAsTrading
259425000 USD
orc Proceeds From Maturities Prepayments And Calls Of Mortgage Backed Securities Categorized As Trading
ProceedsFromMaturitiesPrepaymentsAndCallsOfMortgageBackedSecuritiesCategorizedAsTrading
260834000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
139712000 USD
us-gaap Proceeds From Payments For Securities Purchased Under Agreements To Resell
ProceedsFromPaymentsForSecuritiesPurchasedUnderAgreementsToResell
0 USD
us-gaap Proceeds From Payments For Securities Purchased Under Agreements To Resell
ProceedsFromPaymentsForSecuritiesPurchasedUnderAgreementsToResell
-139738000 USD
orc Proceeds From Net Tba Settlements
ProceedsFromNetTbaSettlements
-3077000 USD
orc Proceeds From Net Tba Settlements
ProceedsFromNetTbaSettlements
-6888000 USD
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
14369000 USD
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
64190000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1063982000 USD
orc Proceeds From Securities Sold Under Agreements To Repurchase
ProceedsFromSecuritiesSoldUnderAgreementsToRepurchase
20879112000 USD
orc Payments For Securities Sold Under Agreements To Repurchase
PaymentsForSecuritiesSoldUnderAgreementsToRepurchase
12663304000 USD
orc Payments For Securities Sold Under Agreements To Repurchase
PaymentsForSecuritiesSoldUnderAgreementsToRepurchase
21152479000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
28008000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
221654000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19447000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
299000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
68000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1105546000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-281996000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
80212000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-42625000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299506000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278655000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236030000 USD
us-gaap Interest Paid Net
InterestPaidNet
3611000 USD
us-gaap Interest Paid Net
InterestPaidNet
31397000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div id="TextBlockContainer275" style="position:relative;font-family:Arial;font-size:14.72px;font-stretch:condensed;color:#000000;line-height:normal;width:733px;height:95px;display:inline-block;border:inherit;margin-left:-2px;margin-right:-2px;"><div id="a2248" style="position:absolute;font-weight:normal;font-style:normal;left:28.475px;top:0px;">The preparation<div style="display:inline-block;width:0.86px"> </div>of financial<div style="display:inline-block;width:1.48px"> </div>statements<div style="display:inline-block;width:1.75px"> </div>in conformity<div style="display:inline-block;width:1.33px"> </div>with GAAP<div style="display:inline-block;width:1.48px"> </div>requires management<div style="display:inline-block;width:0.34px"> </div>to make estimates<div style="display:inline-block;width:0.75px"> </div>and assumptions<div style="display:inline-block;width:0.73px"> </div>that affect </div><div id="a2250" style="position:absolute;font-weight:normal;font-style:normal;left:4.475px;top:19.4px;">the reported<div style="display:inline-block;width:1.3px"> </div>amounts of<div style="display:inline-block;width:1.71px"> </div>assets and<div style="display:inline-block;width:1.61px"> </div>liabilities<div style="display:inline-block;width:1.81px"> </div>and disclosure<div style="display:inline-block;width:1.04px"> </div>of contingent<div style="display:inline-block;width:1.1px"> </div>assets and<div style="display:inline-block;width:1.77px"> </div>liabilities<div style="display:inline-block;width:1.42px"> </div>at the date<div style="display:inline-block;width:1.5px"> </div>of the financial<div style="display:inline-block;width:0.86px"> </div>statements<div style="display:inline-block;width:1.75px"> </div>and </div><div id="a2253" style="position:absolute;font-weight:normal;font-style:normal;left:4.475px;top:38.7px;">the reported<div style="display:inline-block;width:1.3px"> </div>amounts of<div style="display:inline-block;width:1.71px"> </div>revenues and<div style="display:inline-block;width:1.41px"> </div>expenses during<div style="display:inline-block;width:1.01px"> </div>the reporting<div style="display:inline-block;width:1.02px"> </div>period. Actual<div style="display:inline-block;width:1.06px"> </div>results could<div style="display:inline-block;width:1.35px"> </div>differ from<div style="display:inline-block;width:1.71px"> </div>those estimates.<div style="display:inline-block;width:4.07px"> </div>The </div><div id="a2256" style="position:absolute;font-weight:normal;font-style:normal;left:4.475px;top:58.1px;">significant<div style="display:inline-block;width:1.68px"> </div>estimates<div style="display:inline-block;width:1.78px"> </div>affecting the<div style="display:inline-block;width:1.34px"> </div>accompanying<div style="display:inline-block;width:1.52px"> </div>financial<div style="display:inline-block;width:1.79px"> </div>statements<div style="display:inline-block;width:1.59px"> </div>are the fair<div style="display:inline-block;width:1.33px"> </div>values of RMBS<div style="display:inline-block;width:1.04px"> </div>and derivatives.<div style="display:inline-block;width:0.93px"> </div>Management<div style="display:inline-block;width:1.54px"> </div>believes </div><div id="a2260" style="position:absolute;font-weight:normal;font-style:normal;left:4.475px;top:77.4px;">the estimates<div style="display:inline-block;width:1.32px"> </div>and assumptions<div style="display:inline-block;width:0.73px"> </div>underlying<div style="display:inline-block;width:1.74px"> </div>the financial<div style="display:inline-block;width:1.33px"> </div>statements<div style="display:inline-block;width:1.59px"> </div>are reasonable<div style="display:inline-block;width:1.07px"> </div>based on the<div style="display:inline-block;width:1.39px"> </div>information<div style="display:inline-block;width:1.57px"> </div>available as<div style="display:inline-block;width:1.53px"> </div>of June 30,<div style="display:inline-block;width:1.51px"> </div>2021.</div></div>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272842000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
220143000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
106876000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
79363000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299506000 USD
CY2021Q2 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
4671239000 USD
CY2020Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
3726895000 USD
CY2021Q2 orc Gross Amount Of Financial Instruments Posted Not Offset In Balance Sheet
GrossAmountOfFinancialInstrumentsPostedNotOffsetInBalanceSheet
-4435631000 USD
CY2021Q2 orc Gross Amounts Of Cash Posted Not Offset In Balance Sheet
GrossAmountsOfCashPostedNotOffsetInBalanceSheet
-86599000 USD
CY2020Q4 orc Net Amount Of Assets Presented In The Balance Sheet
NetAmountOfAssetsPresentedInTheBalanceSheet
20999000 USD
CY2020Q4 orc Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet
GrossAmountsOfFinancialInstrumentsReceivedNotOffsetInBalanceSheet
0 USD
CY2020Q4 orc Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet
GrossAmountsOfCashCollateralReceivedNotOffsetInBalanceSheet
-6083000 USD
CY2020Q4 orc Net Amount Of Assets
NetAmountOfAssets
14916000 USD
CY2021Q2 orc Gross Amount Of Recognized Liabilties
GrossAmountOfRecognizedLiabilties
4531473000 USD
CY2021Q2 orc Gross Amount Of Liabilties Offset In The Balance Sheet
GrossAmountOfLiabiltiesOffsetInTheBalanceSheet
0 USD
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
10557000 USD
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-91709000 USD
CY2021Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-34915000 USD
CY2020Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-8851000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
106876000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
79363000 USD
CY2021Q2 orc Securities Pledged By Counterparties
SecuritiesPledgedByCounterparties
12187000 USD
CY2020Q4 orc Securities Pledged By Counterparties
SecuritiesPledgedByCounterparties
6456000 USD
CY2021Q2 orc Gross Amount Of Recognized Assets
GrossAmountOfRecognizedAssets
43735000 USD
CY2021Q2 orc Gross Amount Of Assets Offset In The Balance Sheet
GrossAmountOfAssetsOffsetInTheBalanceSheet
0 USD
CY2021Q2 orc Net Amount Of Assets Presented In The Balance Sheet
NetAmountOfAssetsPresentedInTheBalanceSheet
43735000 USD
CY2021Q2 orc Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet
GrossAmountsOfFinancialInstrumentsReceivedNotOffsetInBalanceSheet
0 USD
CY2021Q2 orc Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet
GrossAmountsOfCashCollateralReceivedNotOffsetInBalanceSheet
-12187000 USD
CY2021Q2 orc Net Amount Of Assets
NetAmountOfAssets
31548000 USD
CY2020Q4 orc Gross Amount Of Recognized Assets
GrossAmountOfRecognizedAssets
20999000 USD
CY2020Q4 orc Gross Amount Of Assets Offset In The Balance Sheet
GrossAmountOfAssetsOffsetInTheBalanceSheet
0 USD
CY2020Q4 orc Gross Amount Of Recognized Liabilties
GrossAmountOfRecognizedLiabilties
3628813000 USD
CY2020Q4 orc Gross Amount Of Liabilties Offset In The Balance Sheet
GrossAmountOfLiabiltiesOffsetInTheBalanceSheet
0 USD
CY2020Q4 orc Net Amount Of Liabilities Presented In The Balance Sheet
NetAmountOfLiabilitiesPresentedInTheBalanceSheet
3628813000 USD
CY2020Q4 orc Gross Amount Of Financial Instruments Posted Not Offset In Balance Sheet
GrossAmountOfFinancialInstrumentsPostedNotOffsetInBalanceSheet
-3536757000 USD
CY2020Q4 orc Gross Amounts Of Cash Posted Not Offset In Balance Sheet
GrossAmountsOfCashPostedNotOffsetInBalanceSheet
-78874000 USD
CY2020Q4 orc Net Amount Of Liabilities
NetAmountOfLiabilities
13182000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
41335137 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
221654000 USD
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13019240 shares
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71050000 USD
orc Common Shares Outstanding Earnings Per Share
CommonSharesOutstandingEarningsPerShare
117500000 shares
orc Common Shares Outstanding Earnings Per Share
CommonSharesOutstandingEarningsPerShare
66221000 shares
CY2021Q2 orc Common Shares Outstanding Earnings Per Share
CommonSharesOutstandingEarningsPerShare
117500000 shares
CY2020Q2 orc Common Shares Outstanding Earnings Per Share
CommonSharesOutstandingEarningsPerShare
66221000 shares
orc Unvested Dividend Eligible Shares Outstanding Earnings Per Share
UnvestedDividendEligibleSharesOutstandingEarningsPerShare
0 shares
orc Unvested Dividend Eligible Shares Outstanding Earnings Per Share
UnvestedDividendEligibleSharesOutstandingEarningsPerShare
0 shares
CY2021Q2 orc Unvested Dividend Eligible Shares Outstanding Earnings Per Share
UnvestedDividendEligibleSharesOutstandingEarningsPerShare
0 shares
CY2020Q2 orc Unvested Dividend Eligible Shares Outstanding Earnings Per Share
UnvestedDividendEligibleSharesOutstandingEarningsPerShare
80000 shares
orc Effect Of Weighting
EffectOfWeighting
-25044000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
7366623 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46234000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46234000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42427000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42427000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16865000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16865000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
48772000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
48772000 USD
CY2020Q2 orc Effect Of Weighting
EffectOfWeighting
9000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92456000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65409000 shares
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99489000 shares
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66310000 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
251000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
80000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
251000 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares

Files In Submission

Name View Source Status
0001518621-21-000112-index-headers.html Edgar Link pending
0001518621-21-000112-index.html Edgar Link pending
0001518621-21-000112.txt Edgar Link pending
0001518621-21-000112-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
orc-20210630.xsd Edgar Link pending
orc-20210630_cal.xml Edgar Link unprocessable
orc-20210630_def.xml Edgar Link unprocessable
orc-20210630_lab.xml Edgar Link unprocessable
orc-20210630_pre.xml Edgar Link unprocessable
orc10q20210630.htm Edgar Link pending
orc10q20210630p1i0.gif Edgar Link pending
orc10q20210630x311.htm Edgar Link pending
orc10q20210630x312.htm Edgar Link pending
orc10q20210630x321.htm Edgar Link pending
orc10q20210630x322.htm Edgar Link pending
orc10q20210630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending